Kunal Joshi's Contact Details

Kunal Joshi's Company Details

Stempeutics Research Private Limited

Bengaluru, Karnataka, India • 35 Employees
Research

Stempeutics is a leading Regenerative Medicine company in Bangalore with a stem-cell platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. Company's flagship product, Stempeucel® has received market authorization for the treatment of Critical Limb Ischemia – a major unmet medical need in India. It is the FIRST innovative stem cell based product to get marketing approval in India and Globally. Pan-India commercialization has been commenced by CIPLA, the Indian licensee. It also has three products in Phase 3 stage covering Acute Respiratory Distress Syndrome due to COVID-19 pneumonia, Diabetic Foot Ulcer and Knee Osteoarthritis. Further Stempeutics is conducting Phase 2 trial in Perianal fistula due to Crohn's disease. Stempeucel® has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel® has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by the European Medicines Agency (EMA)Another portfolio being developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from the stem cell derived Growth Factors/Cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Other products ready for marketing are Trichosera™ for Hair application and Optisera™ for under eye applicationWith a strong pipeline in Cell and Stem cell derived products in some of the largest health and personal care segments like OTC Cosmetics (Skin and Hair Care), Diabetes, Osteoarthritis and COVID-ARDS, Stempeutics is poised to transform the Cell therapy space with its India First, Global Next approach.